Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.58 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | TOP1 | P11387 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | VHL | P40337 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | EDNRB | P24530 | 1/20 | 0.41 |
| ▸ | EDNRA | P25101 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30563610 | 1.00 | MKNK1 (0.58) | MKNK1MKNK2PTGS2PTGS1DHODH | |
| Hydrochloric Acid SCHEMBL1420842 | 0.98 | MKNK1 (0.56) | MKNK1MKNK2PTGS2PTGS1DHODH | |
| SCHEMBL30022170 | 0.98 | MKNK1 (0.56) | MKNK1MKNK2PTGS2PTGS1DHODH | |
| SCHEMBL29077101 | 0.98 | MKNK1 (0.56) | MKNK1MKNK2PTGS2PTGS1DHODH | |
| SCHEMBL15730173 | 0.96 | MKNK1 (0.59) | MKNK1MKNK2PTGS2PTGS1DHODH | |
| SCHEMBL15730138 | 0.91 | MKNK1 (0.50) | MKNK1MKNK2PTGS2PTGS1DHODH | |
| SCHEMBL16189062 | 0.89 | MKNK1 (0.57) | MKNK1MKNK2PTGS2PTGS1DHODH | |
| SCHEMBL16189413 | 0.87 | MKNK1 (0.55) | MKNK1MKNK2PTGS2PTGS1DHODH | |
| SCHEMBL30302892 | 0.85 | PTGS2 (0.46) | MKNK1MKNK2PTGS2PTGS1DHODH | |
| SCHEMBL18104239 | 0.84 | MKNK1 (0.56) | MKNK1MKNK2PTGS2PTGS1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119331048-A | Synthesis method of telipopeptide key intermediate | 杭州信海医药科技有限公司 | 2025-01-21 | — | — | CN | claimed |
| US-20260070901-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTPR LTD (GB) | 2026-03-12 | — | — | US | disclosed |
| US-12486232-B2 | Method for preparing meta-functionalized pyridine compound | NANKAI UNIVERSITY (CN) | 2025-12-02 | — | — | US | disclosed |
| US-20250179021-A1 | Method For Preparing Meta-Functionalized Pyridine Compound | CNBM RESEARCH INSTITUTE FOR ADVANCED GLASS MATERIALS GROUP CO., LTD. (CN) | 2025-06-05 | — | — | US | disclosed |
| CN-119331048-A | Synthesis method of telipopeptide key intermediate | 杭州信海医药科技有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-116003312-B | Method for preparing meta-trifluoromethyl thio, difluoromethylthio or trifluoromethyl substituted pyridine compound | 南开大学 | 2024-09-10 | — | — | CN | disclosed |
| CN-118580185-A | Method for synthesizing 3-cyanopyridine oxynitride by microreactor | 南京理工大学 | 2024-09-03 | — | — | CN | disclosed |
| CN-118339941-A | Mixed powder and method for producing same, method for producing organic electroluminescent element using same, method for selecting compound in mixed powder, and composition for vacuum vapor deposition | 出光兴产株式会社 | 2024-07-12 | — | — | CN | disclosed |
| EP-3792288-B1 | TRANSITION METAL COMPOUND FOR OLEFIN POLYMERIZATION CATALYST, AND OLEFIN POLYMERIZATION CATALYST INCLUDING SAME | HANWHA SOLUTIONS CORP (KR) | 2024-05-01 | — | — | EP | disclosed |
| EP-4359398-A1 | AZOLE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | FMC Corporation (US) | 2024-05-01 | — | — | EP | disclosed |
| US-6492524-B1 | SYNTHESIS OF AN ARYL PYRIDINE BASE SAID PROCESS COMPRISING REACTING AN AROMATIC ALDEHYDE OR KETONE OF THE FORMULA R.SUB.1 COR.SUB.2 WHEREIN R.SUB.1 IS PHENYL OR ALKYL PHENYL, R.SUB.2 IS ALKYL WITH 1 TO 2 CARBON ATOMS WITH AN ACROLEIN OR | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2002-12-10 | — | — | US | disclosed |
| WO-2002079161-A1 | A PROCESS FOR THE SYNTHESIS OF AN ARYL PYRIDINE BASE USING A ZEOLITE CATALYST | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2002-10-10 | — | — | WO | disclosed |
| EP-1215206-A1 | PROCESSES FOR THE PREPARATION OF 4(5)-AMINO-5(4)-CARBOXAMIDOIMIDAZOLES AND INTERMEDIATES THEREOF | NIPPON SODA CO., LTD. (JP) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001072711-A1 | 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2001-10-04 | — | — | WO | disclosed |
| EP-0137333-B1 | SPIRO-TRICYCLICAROMATIC SUCCINIMIDE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | ALCON LABORATORIES, INC. (US) | 1992-12-30 | — | — | EP | disclosed |
| US-5153211-A | Enzyme inhibitors | ALCON LABORATORIES, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| US-5070100-A | COMPLICATIONS OF DIABETES | ALCON LABORATORIES, INC. (US) | 1991-12-03 | — | — | US | disclosed |
| US-4864028-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1989-09-05 | — | — | US | disclosed |
| US-4537892-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1985-08-27 | — | — | US | disclosed |
| EP-0137333-A2 | Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase | ALCON LABORATORIES, INC. (US) | 1985-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070901-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CSNK1A1, CSNK2A3, CSNK1G1 | MKNK1 395/4885MKNK2 369/4885PTGS2 1519/4885 |
| US-12486232-B2 | Method for preparing meta-functionalized pyridine compound | GAPVD1, SKP1, PDXK | MKNK1 1166/4885MKNK2 1824/4885PTGS2 1318/4885 |
| US-20250179021-A1 | Method For Preparing Meta-Functionalized Pyridine Compound | GAPVD1, SKP1, PDXK | MKNK1 1166/4885MKNK2 1824/4885PTGS2 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.